Insider Transactions in Q1 2025 at Cyclacel Pharmaceuticals, Inc. (CYCC)

Date	Insider	Transaction	Ownership Type	Shares Traded	Value / Price
Date	Insider	Transaction	Ownership Type	Shares Traded	Value / Price
Feb 26 2025	David E. Lazar Interim CEO	SELL Open market or private sale	Direct	194,628,820 -100.0%	$0 $0.03 P/Share
Feb 26 2025	David E. Lazar Interim CEO	BUY Exercise of conversion of derivative security	Direct	194,628,820 +49.83%	-
Jan 02 2025	David Natan Director	BUY Grant, award, or other acquisition	Direct	100,000 +50.0%	-

Receive a notification when an Institution or Guru buys or sells CYCC shares.

Notify only if

Value

Any

Get notified when an Cyclacel Pharmaceuticals, Inc. insider buys or sells CYCC shares.

Notify only if

Operation

Any

Value

Any

Type

P - Open market or private purchase×

S - Open market or private sale×

V - Transaction voluntarily reported earlier than required×

A - Grant, award, or other acquisition×

D - Sale (or disposition) back to the issuer×

F - Payment of exercise price or tax liability×

I - Discretionary transaction×

M - Exercise of conversion of derivative security×

C - Conversion of derivative security×

E - Expiration of short derivative position×

H - Expiration (or cancellation) of long derivative position with value received×

O - Exercise of out-of-the-money derivative securities×

X - Exercise of in-the-money or at-the-money derivatives securities×

G - Bona fide gift×

L - Small Acquisition×

W - Acquisition or disposition by will or laws×

Z - Deposit into or withdrawal from voting trust×

J - Other acquisition or disposition×

K - Transaction in equity swap or similar instrument×

U - Disposition due to a tender of shares in a change of control transaction×

20 item(s) selected

Receive news related to Cyclacel Pharmaceuticals, Inc.